Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the efficacy, safety, and immunogenicity of the mRNA-1647 cytomegalovirus vaccine in participants undergoing allogeneic hemato…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• mRNA-1647 (Cytomegalovirus vaccine (mRNA-1647))

Snippet

Sponsor: ModernaTX, Inc. | Conditions: Cytomegalovirus Infection | Phase 2 | Status: RECRUITING